![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of RAB29 mRNA] | CTD | PMID:31150632 | (-)-demecolcine | increases expression | ISO | RGD:736472 | 6480464 | Demecolcine results in increased expression of RAB29 mRNA | CTD | PMID:23649840 | 1,2-dimethylhydrazine | multiple interactions | ISO | RGD:733667 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of RAB29 mRNA | CTD | PMID:22206623 | 1,2-dimethylhydrazine | increases expression | ISO | RGD:733667 | 6480464 | 1, 2-Dimethylhydrazine results in increased expression of RAB7L1 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | affects expression | ISO | RGD:733667 | 6480464 | Ethinyl Estradiol affects the expression of RAB29 mRNA | CTD | PMID:17555576 | 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:733667 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of RAB29 mRNA | CTD | PMID:17942748 | 17alpha-ethynylestradiol | increases expression | ISO | RGD:733667 | 6480464 | Ethinyl Estradiol results in increased expression of RAB29 mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:733667 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of RAB29 mRNA | CTD | PMID:17942748 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of RAB29 mRNA | CTD | PMID:32109520 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of RAB29 mRNA | CTD | PMID:26232522 | 2,4-dibromophenyl 2,4,5-tribromophenyl ether | increases expression | ISO | RGD:736472 | 6480464 | 2 more ... | CTD | PMID:26705709 | 2,6-dinitrotoluene | affects expression | EXP | | 6480464 | 2, 6-dinitrotoluene affects the expression of RAB29 mRNA | CTD | PMID:21346803 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:736472 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of RAB29 mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | increases expression | ISO | RGD:733667 | 6480464 | bis(4-hydroxyphenyl)sulfone results in increased expression of RAB29 mRNA | CTD | PMID:30951980 | 6-propyl-2-thiouracil | increases expression | EXP | | 6480464 | Propylthiouracil results in increased expression of RAB29 mRNA | CTD | PMID:24780913 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of RAB29 mRNA | CTD | PMID:31881176 | acrylamide | increases expression | ISO | RGD:736472 | 6480464 | Acrylamide results in increased expression of RAB29 mRNA | CTD | PMID:32763439 | all-trans-retinoic acid | increases expression | ISO | RGD:736472 | 6480464 | Tretinoin results in increased expression of RAB29 mRNA | CTD | PMID:33167477 | antirheumatic drug | decreases expression | ISO | RGD:736472 | 6480464 | Antirheumatic Agents results in decreased expression of RAB29 mRNA | CTD | PMID:24449571 | aristolochic acid A | increases expression | ISO | RGD:736472 | 6480464 | aristolochic acid I results in increased expression of RAB29 mRNA | CTD | PMID:33212167 | atrazine | increases expression | ISO | RGD:736472 | 6480464 | Atrazine results in increased expression of RAB29 mRNA | CTD | PMID:22378314 | belinostat | increases expression | ISO | RGD:736472 | 6480464 | belinostat results in increased expression of RAB29 mRNA | CTD | PMID:27188386 | benzo[a]pyrene diol epoxide I | decreases expression | ISO | RGD:736472 | 6480464 | 7 more ... | CTD | PMID:20018196 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of RAB29 mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of RAB29 mRNA | CTD | PMID:34947998 | bisphenol A | increases expression | ISO | RGD:736472 | 6480464 | bisphenol A results in increased expression of RAB29 mRNA | CTD | PMID:29275510 | bisphenol A | increases expression | ISO | RGD:733667 | 6480464 | bisphenol A results in increased expression of RAB29 mRNA | CTD | PMID:30951980 | bisphenol F | multiple interactions | ISO | RGD:736472 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of RAB29 mRNA | CTD | PMID:28628672 | bisphenol F | increases expression | ISO | RGD:733667 | 6480464 | bisphenol F results in increased expression of RAB29 mRNA | CTD | PMID:30951980 | buspirone | increases expression | EXP | | 6480464 | Buspirone results in increased expression of RAB29 mRNA | CTD | PMID:24136188 | cadmium sulfate | multiple interactions | ISO | RGD:733667 | 6480464 | cadmium sulfate affects the reaction [MTF1 affects the expression of RAB29 mRNA] | CTD | PMID:16221973 | carbon nanotube | increases expression | ISO | RGD:733667 | 6480464 | Nanotubes, Carbon results in increased expression of RAB29 mRNA | CTD | PMID:25554681 | cisplatin | increases expression | ISO | RGD:736472 | 6480464 | Cisplatin results in increased expression of RAB7L1 mRNA | CTD | PMID:27392435 | cisplatin | multiple interactions | ISO | RGD:736472 | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of RAB7L1 mRNA | CTD | PMID:27392435 | coumestrol | decreases expression | ISO | RGD:736472 | 6480464 | Coumestrol results in decreased expression of RAB29 mRNA | CTD | PMID:19167446 | cyclosporin A | decreases expression | ISO | RGD:736472 | 6480464 | Cyclosporine results in decreased expression of RAB29 mRNA | CTD | PMID:20106945 | dexamethasone | multiple interactions | ISO | RGD:736472 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of RAB29 mRNA | CTD | PMID:28628672 | dibutyl phthalate | decreases expression | EXP | | 6480464 | Dibutyl Phthalate results in decreased expression of RAB29 mRNA | CTD | PMID:21266533 | dioxygen | affects methylation | ISO | RGD:733667 | 6480464 | Oxygen deficiency affects the methylation of RAB29 promoter | CTD | PMID:24205000 | dioxygen | decreases expression | ISO | RGD:733667 | 6480464 | Oxygen deficiency results in decreased expression of RAB29 mRNA | CTD | PMID:24205000 | dorsomorphin | multiple interactions | ISO | RGD:736472 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | doxorubicin | decreases expression | ISO | RGD:736472 | 6480464 | Doxorubicin results in decreased expression of RAB29 mRNA | CTD | PMID:29803840 | entinostat | increases expression | ISO | RGD:736472 | 6480464 | entinostat results in increased expression of RAB29 mRNA | CTD | PMID:26272509, PMID:27188386 | entinostat | multiple interactions | ISO | RGD:736472 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB29 mRNA | CTD | PMID:27188386 | fluoranthene | multiple interactions | ISO | RGD:733667 | 6480464 | [1-methylanthracene co-treated with fluoranthene] results in decreased expression of RAB29 mRNA | CTD | PMID:28329830 | flutamide | decreases expression | EXP | | 6480464 | Flutamide results in decreased expression of RAB29 mRNA | CTD | PMID:24136188 | folic acid | decreases expression | ISO | RGD:733667 | 6480464 | Folic Acid results in decreased expression of RAB7L1 mRNA | CTD | PMID:25629700 | folic acid | multiple interactions | ISO | RGD:733667 | 6480464 | [1, 2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of RAB29 mRNA | CTD | PMID:22206623 | gentamycin | increases expression | EXP | | 6480464 | Gentamicins results in increased expression of RAB29 mRNA | CTD | PMID:22061828 | indometacin | multiple interactions | ISO | RGD:736472 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of RAB29 mRNA | CTD | PMID:28628672 | lead(0) | affects expression | ISO | RGD:736472 | 6480464 | Lead affects the expression of RAB7L1 mRNA | CTD | PMID:28903495 | lead(2+) | affects expression | ISO | RGD:736472 | 6480464 | Lead affects the expression of RAB7L1 mRNA | CTD | PMID:28903495 | linsidomine | increases oxidation | EXP | | 6480464 | linsidomine results in increased oxidation of RAB29 protein | CTD | PMID:28086193 | methyl methanesulfonate | decreases expression | ISO | RGD:736472 | 6480464 | Methyl Methanesulfonate results in decreased expression of RAB29 mRNA | CTD | PMID:23649840 | nickel atom | increases expression | ISO | RGD:736472 | 6480464 | Nickel results in increased expression of RAB29 mRNA | CTD | PMID:24768652, PMID:25583101 | nimesulide | decreases expression | EXP | | 6480464 | nimesulide results in decreased expression of RAB29 mRNA | CTD | PMID:24136188 | paracetamol | decreases expression | ISO | RGD:736472 | 6480464 | Acetaminophen results in decreased expression of RAB29 mRNA | CTD | PMID:21420995 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:733667 | 6480464 | [perfluorooctane sulfonic acid co-treated with Pectins] results in decreased expression of RAB29 mRNA | CTD | PMID:36331819 | SB 431542 | multiple interactions | ISO | RGD:736472 | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | silicon dioxide | increases expression | ISO | RGD:736472 | 6480464 | Silicon Dioxide analog results in increased expression of RAB29 mRNA | CTD | PMID:25895662 | silver atom | increases expression | ISO | RGD:733667 | 6480464 | Silver results in increased expression of RAB29 mRNA | CTD | PMID:27131904 | silver(0) | increases expression | ISO | RGD:733667 | 6480464 | Silver results in increased expression of RAB29 mRNA | CTD | PMID:27131904 | sodium arsenate | increases expression | ISO | RGD:733667 | 6480464 | sodium arsenate results in increased expression of RAB29 mRNA | CTD | PMID:30953684 | sunitinib | increases expression | ISO | RGD:736472 | 6480464 | Sunitinib results in increased expression of RAB29 mRNA | CTD | PMID:31533062 | tamoxifen | affects expression | ISO | RGD:733667 | 6480464 | Tamoxifen affects the expression of RAB29 mRNA | CTD | PMID:17555576 | temozolomide | decreases expression | ISO | RGD:736472 | 6480464 | Temozolomide results in decreased expression of RAB29 mRNA | CTD | PMID:31758290 | tert-butyl hydroperoxide | increases expression | ISO | RGD:736472 | 6480464 | tert-Butylhydroperoxide results in increased expression of RAB29 mRNA | CTD | PMID:15336504 | testosterone | decreases expression | ISO | RGD:736472 | 6480464 | Testosterone results in decreased expression of RAB7L1 mRNA | CTD | PMID:33359661 | tetrachloromethane | affects expression | ISO | RGD:733667 | 6480464 | Carbon Tetrachloride affects the expression of RAB29 mRNA | CTD | PMID:17484886 | tetrachloromethane | decreases expression | ISO | RGD:733667 | 6480464 | Carbon Tetrachloride results in decreased expression of RAB29 mRNA | CTD | PMID:31919559 | tetrachloromethane | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of RAB29 mRNA] | CTD | PMID:31150632 | tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of RAB29 mRNA | CTD | PMID:31150632 | thimerosal | decreases expression | ISO | RGD:736472 | 6480464 | Thimerosal results in decreased expression of RAB29 mRNA | CTD | PMID:27188386 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of RAB29 mRNA | CTD | PMID:34492290 | tipifarnib | increases expression | EXP | | 6480464 | tipifarnib results in increased expression of RAB29 mRNA | CTD | PMID:16403772 | topotecan | affects response to substance | ISO | RGD:736472 | 6480464 | RAB29 protein affects the susceptibility to Topotecan | CTD | PMID:16217747 | trichostatin A | increases expression | ISO | RGD:736472 | 6480464 | trichostatin A results in increased expression of RAB29 mRNA | CTD | PMID:24935251, PMID:27188386 | triptonide | affects expression | ISO | RGD:733667 | 6480464 | triptonide affects the expression of RAB29 mRNA | CTD | PMID:33045310 | urethane | decreases expression | ISO | RGD:736472 | 6480464 | Urethane results in decreased expression of RAB29 mRNA | CTD | PMID:28818685 | valproic acid | decreases methylation | ISO | RGD:736472 | 6480464 | Valproic Acid results in decreased methylation of RAB29 gene | CTD | PMID:29154799 | valproic acid | affects expression | ISO | RGD:736472 | 6480464 | Valproic Acid affects the expression of RAB29 mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | RGD:736472 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB29 mRNA | CTD | PMID:27188386 | valproic acid | increases expression | ISO | RGD:736472 | 6480464 | Valproic Acid results in increased expression of RAB29 mRNA, Valproic Acid results in increased expression of RAB7L1 mRNA | CTD | PMID:19101580 more ... | vincristine | increases expression | ISO | RGD:736472 | 6480464 | Vincristine results in increased expression of RAB29 mRNA | CTD | PMID:23649840 | vorinostat | increases expression | ISO | RGD:736472 | 6480464 | vorinostat results in increased expression of RAB29 mRNA | CTD | PMID:27188386 | |